Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S, Shah U, Hassoun H, Smith E, Lesokhin A, Mailankody S, Landgren O, Thoren K.

Br J Haematol. 2020 Feb 5. doi: 10.1111/bjh.16443. [Epub ahead of print]

PMID:
32026474
2.

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Salcedo M, Lendvai N, Mastey D, Schlossman J, Hultcrantz M, Korde N, Mailankody S, Lesokhin A, Hassoun H, Smith E, Shah U, Diab V, Werner K, Landau H, Lahoud O, Drullinsky P, Shah G, Chung D, Scordo M, Giralt S, Landgren O.

Clin Lymphoma Myeloma Leuk. 2019 Dec 26. pii: S2152-2650(19)32235-9. doi: 10.1016/j.clml.2019.12.013. [Epub ahead of print] No abstract available.

PMID:
32001193
3.

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, Mailankody S, Landgren O, Figg WD.

Sci Rep. 2019 Oct 16;9(1):14884. doi: 10.1038/s41598-019-51446-9.

4.

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O.

Am J Hematol. 2019 Dec;94(12):1364-1373. doi: 10.1002/ajh.25641. Epub 2019 Oct 21.

PMID:
31571261
5.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1568. [Epub ahead of print]

PMID:
31318385
6.

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

Kazandjian D, Hill E, Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, Korde N, Mailankody S, Dew A, Papaemmanuil E, Maric I, Kwok M, Landgren O.

Blood Cancer J. 2019 Feb 4;9(2):15. doi: 10.1038/s41408-019-0177-9.

7.

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O.

JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457. No abstract available.

8.

Dietary intake is associated with risk of multiple myeloma and its precursor disease.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Steingrimsdottir L, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Torfadottir JE, Kristinsson SY.

PLoS One. 2018 Nov 1;13(11):e0206047. doi: 10.1371/journal.pone.0206047. eCollection 2018.

9.

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, Mailankody S, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O.

Bone Marrow Transplant. 2018 Nov;53(11):1445-1449. doi: 10.1038/s41409-018-0170-0. Epub 2018 May 4.

10.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, Landau H, Korde N, Mailankody S, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O.

Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8. No abstract available.

11.

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.

12.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

13.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, Kenny S, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2018 Apr;24(4):871-876. doi: 10.1016/j.bbmt.2017.12.795. Epub 2017 Dec 27.

14.

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.

Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV.

Blood Cancer J. 2017 Oct 20;7(10):e618. doi: 10.1038/bcj.2017.97.

15.

Host-related immunodeficiency in the development of multiple myeloma.

Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O.

Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.

16.

Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.

Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O.

Obesity (Silver Spring). 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.

17.

Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.

Salem DA, Korde N, Venzon DJ, Liewehr DJ, Maric I, Calvo KR, Braylan R, Tembhare PR, Yuan CM, Landgren CO, Stetler-Stevenson M.

Leuk Lymphoma. 2018 Jan;59(1):178-186. doi: 10.1080/10428194.2017.1321746. Epub 2017 May 25.

18.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.

19.

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.

Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO.

Leuk Lymphoma. 2017 Dec;58(12):2962-2965. doi: 10.1080/10428194.2017.1312382. Epub 2017 May 9. No abstract available.

PMID:
28482750
20.

Treatment of high-risk smoldering myeloma.

Korde N.

Semin Oncol. 2016 Dec;43(6):695-696. doi: 10.1053/j.seminoncol.2016.11.005. Epub 2016 Nov 14.

PMID:
28061988
21.

Proteomic profiling in plasma cell disorders: a feasibility study.

Mailankody S, Devlin SM, Korde N, Lendvai N, Lesokhin A, Landau H, Hassoun H, Ballagi A, Ekman D, Chung DJ, Patel M, Koehne G, Giralt S, Landgren O.

Leuk Lymphoma. 2017 Jul;58(7):1757-1759. doi: 10.1080/10428194.2016.1258699. Epub 2016 Dec 2. No abstract available.

22.

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O.

Leuk Lymphoma. 2017 Mar;58(3):639-645. doi: 10.1080/10428194.2016.1214953. Epub 2016 Aug 9.

23.

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.

Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, Landgren O, Childs RW.

Clin Cancer Res. 2016 Nov 1;22(21):5211-5222. Epub 2016 Jun 15.

24.

Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.

Ogunniyi A, Rodriguez M, Devlin S, Adel N, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, Mailankody S, Korde N, Reich L, Landgren O, Giralt S, Hassoun H.

Leuk Lymphoma. 2017 May;58(5):1123-1129. doi: 10.1080/10428194.2016.1239261. Epub 2016 Oct 13.

25.

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Murata K, McCash SI, Carroll B, Lesokhin AM, Hassoun H, Lendvai N, Korde NS, Mailankody S, Landau HJ, Koehne G, Chung DJ, Giralt SA, Ramanathan LV, Landgren O.

Clin Biochem. 2018 Jan;51:66-71. doi: 10.1016/j.clinbiochem.2016.09.015. Epub 2016 Sep 21.

26.

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Lendvai N, Yee AJ, Tsakos I, Alexander A, Devlin SM, Hassoun H, Korde N, Lesokhin AM, Landau H, Mailankody S, Koehne G, Chung DJ, Landgren O, Raje NS, Giralt S.

Blood. 2016 May 12;127(19):2355-6. doi: 10.1182/blood-2016-01-694786. Epub 2016 Mar 28. No abstract available.

27.

Monoclonal gammopathy-associated pure red cell aplasia.

Korde N, Zhang Y, Loeliger K, Poon A, Simakova O, Zingone A, Costello R, Childs R, Noel P, Silver S, Kwok M, Mo C, Young N, Landgren O, Sloand E, Maric I.

Br J Haematol. 2016 Jun;173(6):876-83. doi: 10.1111/bjh.14012. Epub 2016 Mar 21.

28.

Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.

Sundararajan S, Kumar A, Korde N, Agarwal A.

Curr Hematol Malig Rep. 2016 Apr;11(2):102-10. doi: 10.1007/s11899-016-0305-6. Review.

PMID:
26894382
29.

Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.

Afifi S, Adel NG, Devlin S, Duck E, Vanak J, Landau H, Chung DJ, Lendvai N, Lesokhin A, Korde N, Reich L, Landgren O, Giralt S, Hassoun H.

Bone Marrow Transplant. 2016 Apr;51(4):546-52. doi: 10.1038/bmt.2015.322. Epub 2016 Jan 4.

PMID:
26726942
30.

Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O.

Leuk Lymphoma. 2016 May;57(5):1114-21. doi: 10.3109/10428194.2015.1090572. Epub 2016 Apr 7.

31.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.

32.

Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A, Costello R, Zhang Y, Kurlander RJ, Korde N, Roccaro AM, Ghobrial IM, Landgren O, Calvo KR.

J Mol Diagn. 2015 Nov;17(6):669-78. doi: 10.1016/j.jmoldx.2015.06.006. Epub 2015 Sep 30.

33.

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.

Acosta-Alvear D, Cho MY, Wild T, Buchholz TJ, Lerner AG, Simakova O, Hahn J, Korde N, Landgren O, Maric I, Choudhary C, Walter P, Weissman JS, Kampmann M.

Elife. 2015 Sep 1;4:e08153. doi: 10.7554/eLife.08153.

34.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O.

JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.

35.

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY.

JAMA Oncol. 2015 May;1(2):168-74. doi: 10.1001/jamaoncol.2015.23.

PMID:
26181017
36.

Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.

Kazandjian D, Mailankody S, Korde N, Landgren O.

Clin Adv Hematol Oncol. 2014 Sep;12(9):578-87. Review.

PMID:
25654479
37.

Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O.

Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Review.

PMID:
25622976
38.

The road to treating smoldering multiple myeloma.

Korde N, Mailankody S, Landgren O.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S59-64. doi: 10.1016/j.clml.2014.04.012. Review.

PMID:
25486957
39.

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.

Manasanch EE, Korde N, Mailankody S, Tageja N, Bhutani M, Roschewski M, Landgren O.

Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. No abstract available.

40.

Dilemmas in treating smoldering multiple myeloma.

Ahn IE, Mailankody S, Korde N, Landgren O.

J Clin Oncol. 2015 Jan 1;33(1):115-23. doi: 10.1200/JCO.2014.56.4351. Epub 2014 Nov 24. Review.

41.

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, Kazandjian D, Carter G, Steinberg SM, Zuchlinski D, Mulquin M, Calvo K, Maric I, Roschewski M, Korde N, Braylan R, Landgren O, Stetler-Stevenson M.

Leuk Lymphoma. 2015 May;56(5):1416-24. doi: 10.3109/10428194.2014.955020. Epub 2014 Oct 30.

42.

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O.

Cytokine. 2014 Oct;69(2):294-7. doi: 10.1016/j.cyto.2014.05.017. Epub 2014 Jul 17.

43.

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.

Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. No abstract available.

44.

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.

Leuk Res. 2014 Mar;38(3):371-6. doi: 10.1016/j.leukres.2013.12.007. Epub 2013 Dec 11.

45.

Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.

McShane CM, Murray LJ, Landgren O, O'Rorke MA, Korde N, Kunzmann AT, Ismail MR, Anderson LA.

Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):332-42. doi: 10.1158/1055-9965.EPI-13-0695. Epub 2014 Jan 22. Review.

46.

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.

Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, Kumar SK, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ 3rd, Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, Rajkumar SV.

Leukemia. 2014 Jul;28(7):1537-42. doi: 10.1038/leu.2014.34. Epub 2014 Jan 20.

47.

Minimal residual disease: what are the minimum requirements?

Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O.

J Clin Oncol. 2014 Feb 10;32(5):475-6. doi: 10.1200/JCO.2013.52.1955. Epub 2014 Jan 13. No abstract available.

PMID:
24419126
48.

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.

Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M, Landgren O.

Leuk Lymphoma. 2014 Aug;55(8):1707-14. doi: 10.3109/10428194.2013.828351. Epub 2014 Jan 24. Review.

PMID:
24261677
49.

Smoldering multiple myeloma: present position and potential promises.

Tageja N, Manasanch EE, Korde N, Kwok M, Mailankody S, Bhutani M, Roschewski M, Landgren O.

Eur J Haematol. 2014 Jan;92(1):1-12. doi: 10.1111/ejh.12205. Epub 2013 Nov 26. Review.

PMID:
24112232
50.

Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Bhutani M, Turkbey B, Tan E, Kemp TJ, Pinto LA, Berg AR, Korde N, Minter AR, Weiss BM, Mena E, Lindenberg L, Aras O, Purdue MP, Hofmann JN, Steinberg SM, Calvo KR, Choyke PL, Maric I, Kurdziel K, Landgren O.

Leukemia. 2014 Feb;28(2):413-6. doi: 10.1038/leu.2013.268. Epub 2013 Sep 18. No abstract available.

Supplemental Content

Support Center